jerry submitted, created time 6 months 5 days (jco.ascopubs.org)

This study tells us that both clinical patient characteristics and molecular tumor markers may be used to predict the likelihood of response to EGFR TKI therapy.

It is likely—indeed probably inevitable—that a panel of tests will be used in the not too distant future to determine which patients are likely to respond, and of almost equal importance, to determine which patients are unlikely to derive benefit from EGFR inhibitor therapy. At this time, molecular selection of patients for first-line therapy with EGFR TKIs is not quite ready for prime time and we eagerly await the results of the prospectively designed randomized trials.

Keywords: TKI EGFR cancer lung cancer Non–Small-Cell Lung Cancer